ACTA1 and Hepatic fibrosis: The researchers observed that the EV-mediated delivery of the CRISPR/dCas9-VP64 system to activated HSCs in vivo induced the reduction of the mRNA and protein levels of α-SMA and collagen I, providing a promising gene therapy strategy for treating hepatic fibrosis through HSC reprogramming.